.jpeg)
2026-03-04 07:32:53
Explore whether Ixazomib (Ninlaro) requires long-term use for Multiple Myeloma. Analyze its critical role in induction and maintenance therapy, the impact of long-term adherence on extending progression-free survival, and expert advice on side effect management and personalized discontinuation strategies.
2026-02-28 03:31:21
Isatuximab (Sarclisa) is a CD38-targeting monoclonal antibody approved for relapsed/refractory and newly diagnosed Multiple Myeloma. Its mechanism involves apoptosis induction, ADCC immune killing, and enzymatic inhibition. Clinical data confirms extended Progression-Free Survival (PFS) and improved MRD negativity with combination regimens. This guide covers IV infusion protocols, Infusion-Related Reaction (IRR) management, and patient quality of life insights for optimized treatment decisions.
2026-02-09 04:16:06
As an agonist of the thrombopoietin receptor, eltrombopag has significant therapeutic effects in chronic ITP (adults and children), hepatitis C-related thrombocytopenia, and severe aplastic anemia. It can increase platelet count, reduce bleeding risk, assist in antiviral therapy, and promote hematopoietic reconstruction. Clinical data has verified its multi scenario application value.
2025-10-19 11:44:20
